Trends in Clinical Pharmacokinetics

Clinical Pharmacokinetics

Volumn 24, Issue 1, 1993, Pages 1-9

  Reidenberg, Marcus M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS; DIGITOXIN; HYDRALAZINE; MEPACRINE; QUININE; SUXAMETHONIUM;

CLINICAL PHARMACY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACETYLATION; DRUG ELIMINATION; DRUG RESEARCH; HISTORY OF MEDICINE; HUMAN; KIDNEY FAILURE; NONHUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ANIMAL; HUMAN; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 0027476216     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199324010-00001     Document Type: Article

References (21)

1. Physicochemical and biochemical aspects of pharmacology
2. Pharmacologic basis of cardiac therapy
3. Studies on digitalis in ambulatory cardiac patients
4. The persistence of action of the digitalin
5. Acetylprocainamide therapy in patients, with previous procainamide-induced lupus syndrome
6. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide
7. The familial incidence of low pseudocho-linesterase level
8. Pharmaceutical formulation and therapeutic efficacy
9. The metabolism of 1-hydrazinophthalazine
10. Bioavailability and generic prescribing
11. Notes on digitalis medication
12. Relationship of acetyltransferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine
13. Hydralazine elimination in man
14. The polymorphic acetylation of procainamide by man
15. The rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients
16. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function
17. The study of antimalarials and antimalarial activity in the human malarials
18. Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with ‘curability’ of experimental leukemia
19. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome